Literature DB >> 11213832

Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma.

H Sato1, T Hasegawa, Y Kanai, Y Tsutsumi, Y Osamura, Y Abe, H Sakai, S Hirohashi.   

Abstract

E-cadherin, the major intercellular adhesion molecule of epithelial cells, is important in determining the architecture of sarcomas, especially those showing epithelioid features. In addition to its role in cell adhesion, beta-catenin, a cadherin undercoat protein, has been shown to function as a downstream transcriptional activator of the Wnt/Wingless signaling pathway. In order to evaluate the significance of the cadherin cell adhesion system and the Wnt/Wingless signaling pathway in the morphogenesis and/or tumorigenesis of synovial sarcoma (a major type of sarcoma with epithelioid features), immunoreactivity for pan-cadherin, E-cadherin, and their undercoat proteins (alpha-, beta-,and gamma-catenins and p120) was evaluated in 15 synovial sarcomas. Immunoreactivity for pan-cadherin, E-cadherin, alpha-catenin, beta-catenin, and p120 was observed in all 15 specimens. Immunoreactivity for pan-cadherin was stronger than that for E-cadherin. Expression of gamma-catenin was detected in ten specimens. Although beta-catenin was observed only at the cell-cell boundaries in four specimens, it was present in the nucleus and cytoplasm and at the cell-cell boundaries in the other 11, suggesting constitutional activation of the Wnt/Wingless signaling pathway in synovial sarcoma. Direct sequencing for exon 3 of the beta-catenin gene, however, revealed no mutations in any of the 15 specimens. In conclusion, other types of cadherin besides E-cadherin, together with cadherin undercoat proteins, may play a role in cell adhesion in synovial sarcoma. Furthermore, mechanisms other than mutation of exon 3 of the beta-catenin gene may activate the Wnt/Wingless signaling pathway in this type of tumor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11213832     DOI: 10.1007/s004280000318

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

Review 1.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

2.  Targeting the Wnt pathway in synovial sarcoma models.

Authors:  Whitney Barham; Andrea L Frump; Taylor P Sherrill; Christina B Garcia; Kenyi Saito-Diaz; Michael N VanSaun; Barbara Fingleton; Linda Gleaves; Darren Orton; Mario R Capecchi; Timothy S Blackwell; Ethan Lee; Fiona Yull; Josiane E Eid
Journal:  Cancer Discov       Date:  2013-08-06       Impact factor: 39.397

3.  Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.

Authors:  Iwao Mikami; Liang You; Biao He; Zhidong Xu; Sonny Batra; Amie Y Lee; Julien Mazieres; Noemi Reguart; Kazutsugu Uematsu; Kiyoshi Koizumi; David M Jablons
Journal:  BMC Cancer       Date:  2005-05-24       Impact factor: 4.430

4.  The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.

Authors:  Luisa Cironi; Tanja Petricevic; Victor Fernandes Vieira; Paolo Provero; Carlo Fusco; Sandrine Cornaz; Giulia Fregni; Igor Letovanec; Michel Aguet; Ivan Stamenkovic
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

5.  Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.

Authors:  Tetsuya Sekita; Tesshi Yamada; Eisuke Kobayashi; Akihiko Yoshida; Toru Hirozane; Akira Kawai; Yuko Uno; Hideki Moriyama; Masaaki Sawa; Yuichi Nagakawa; Akihiko Tsuchida; Morio Matsumoto; Masaya Nakamura; Robert Nakayama; Mari Masuda
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

6.  Next generation sequencing in synovial sarcoma reveals novel gene mutations.

Authors:  Myrella Vlenterie; Melissa H S Hillebrandt-Roeffen; Uta E Flucke; Patricia J T A Groenen; Bastiaan B J Tops; Eveline J Kamping; Rolph Pfundt; Diederik R H de Bruijn; Ad H M Geurts van Kessel; Han J H J M van Krieken; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Oncotarget       Date:  2015-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.